Literature DB >> 33201181

Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19.

Víctor Manuel Becerra-Muñoz1, Iván J Núñez-Gil2, Charbel Maroun Eid3, Marcos García Aguado4, Rodolfo Romero5, Jia Huang6, Alba Mulet7, Fabrizio Ugo8, Francesco Rametta8, Christoph Liebetrau9, Alvaro Aparisi10, Inmaculada Fernández-Rozas11, María C Viana-Llamas12, Gisela Feltes13, Martino Pepe14, Luis A Moreno-Rondón15, Enrico Cerrato16, Sergio Raposeiras-Roubín17, Emilio Alfonso18, Ana Carrero-Fernández19, Luis Buzón-Martín20, Mohammad Abumayyaleh21,22, Adelina Gonzalez23, Antonio Fernández Ortiz2, Carlos Macaya2, Vicente Estrada2, Cristina Fernández-Pérez2, Juan José Gómez-Doblas1.   

Abstract

BACKGROUND: the coronavirus disease 2019 (COVID-19) is characterized by poor outcomes and mortality, particularly in older patients.
METHODS: post hoc analysis of the international, multicentre, 'real-world' HOPE COVID-19 registry. All patients aged ≥65 years hospitalised for COVID-19 were selected. Epidemiological, clinical, analytical and outcome data were obtained. A comparative study between two age subgroups, 65-74 and ≥75 years, was performed. The primary endpoint was all cause in-hospital mortality.
RESULTS: about, 1,520 patients aged ≥65 years (60.3% male, median age of 76 [IQR 71-83] years) were included. Comorbidities such as hypertension (69.2%), dyslipidaemia (48.6%), cardiovascular diseases (any chronic heart disease in 38.4% and cerebrovascular disease in 12.5%), and chronic lung disease (25.3%) were prevalent, and 49.6% were on ACEI/ARBs. Patients aged 75 years and older suffered more in-hospital complications (respiratory failure, heart failure, renal failure, sepsis) and a significantly higher mortality (18.4 vs. 48.2%, P < 0.001), but fewer admissions to intensive care units (11.2 vs. 4.8%). In the overall cohort, multivariable analysis demonstrated age ≥75 (OR 3.54), chronic kidney disease (OR 3.36), dementia (OR 8.06), peripheral oxygen saturation at admission <92% (OR 5.85), severe lymphopenia (<500/mm3) (OR 3.36) and qSOFA (Quick Sequential Organ Failure Assessment Score) >1 (OR 8.31) to be independent predictors of mortality.
CONCLUSION: patients aged ≥65 years hospitalised for COVID-19 had high rates of in-hospital complications and mortality, especially among patients 75 years or older. Age ≥75 years, dementia, peripheral oxygen saturation <92%, severe lymphopenia and qSOFA scale >1 were independent predictors of mortality in this population.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Coronavirus disease 2019; SARS-CoV-2; comorbidities; older adults

Year:  2021        PMID: 33201181      PMCID: PMC7717146          DOI: 10.1093/ageing/afaa258

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  24 in total

1.  Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action.

Authors:  Lin Liu; Shu-Yu Ni; Wei Yan; Qing-Dong Lu; Yi-Miao Zhao; Ying-Ying Xu; Huan Mei; Le Shi; Kai Yuan; Ying Han; Jia-Hui Deng; Yan-Kun Sun; Shi-Qiu Meng; Zheng-Dong Jiang; Na Zeng; Jian-Yu Que; Yong-Bo Zheng; Bei-Ni Yang; Yi-Miao Gong; Arun V Ravindran; Thomas Kosten; Yun Kwok Wing; Xiang-Dong Tang; Jun-Liang Yuan; Ping Wu; Jie Shi; Yan-Ping Bao; Lin Lu
Journal:  EClinicalMedicine       Date:  2021-09-08

2.  Barthel's Index: A Better Predictor for COVID-19 Mortality Than Comorbidities.

Authors:  João Cordeiro da Costa; Maria Conceição Manso; Susana Gregório; Márcia Leite; João Moreira Pinto
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-06-23

Review 3.  Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Abraham Degarege; Zaeema Naveed; Josiane Kabayundo; David Brett-Major
Journal:  Pathogens       Date:  2022-05-10

4.  Patient Perspectives on the COVID-19 Vaccine: A Pilot Survey Study of Patients in Endocrinology Clinics.

Authors:  Pushyami Mikkilineni; Rebecca Simon; Arti Bhan; Sudhaker D Rao
Journal:  Endocr Pract       Date:  2022-07-03       Impact factor: 3.701

5.  Incidence and predictors of mortality among COVID-19 patients admitted to treatment centers in North West Ethiopia; A retrospective cohort study, 2021.

Authors:  Belayneh Mengist; Zelalem Animut; Tadesse Tolossa
Journal:  Int J Afr Nurs Sci       Date:  2022-04-30

Review 6.  Research Progress in the Treatment of Complications and Sequelae of COVID-19.

Authors:  Jinpeng Wang; Kuoyun Zhu; Yuchuan Xue; Guangfu Wen; Lin Tao
Journal:  Front Med (Lausanne)       Date:  2021-12-02

7.  Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19.

Authors:  Tony Zitek; Kathleen Jodoin; Tarang Kheradia; Ryan Napolillo; Michael T Dalley; Faith Quenzer; David A Farcy
Journal:  Am J Emerg Med       Date:  2021-11-02       Impact factor: 4.093

8.  Margins of beneficial daily dosage of supplements in prevention of COVID-19.

Authors:  Vladimir Ajdžanovic; Branko Filipovic; Branka Šošic-Jurjevic; Marko Miler; Verica Miloševic
Journal:  EXCLI J       Date:  2021-04-26       Impact factor: 4.068

9.  A rapid and feasible tool for clinical decision making in community-dwelling patients with COVID-19 and those admitted to emergency departments: the Braden-LDH-HorowITZ Assessment-BLITZ.

Authors:  Erik Lagolio; Jacopo Demurtas; Thomas Benzing; Maria Cristina Polidori; Roberto Buzzetti; Giorgio Cortassa; Stefania Bottone; Laura Spadafora; Cristina Cocino; Lee Smith
Journal:  Intern Emerg Med       Date:  2021-07-28       Impact factor: 5.472

Review 10.  The Identikit of Patient at Risk for Severe COVID-19 and Death: The Dysregulation of Renin-Angiotensin System as the Common Theme.

Authors:  Riccardo Sarzani; Massimiliano Allevi; Federico Giulietti; Chiara Di Pentima; Serena Re; Piero Giordano; Francesco Spannella
Journal:  J Clin Med       Date:  2021-12-15       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.